Overview

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective disorder, major depression or bipolar disorder with psychotic features. This study evaluates symptom response as well as general health indicators such as body mass index, glucose, prolactin, and cholesterol levels at baseline, month (M)1, M3, M6 and M12.

Phase:

N/A

Details

Lead Sponsor:

Vanderbilt University
Vanderbilt University Medical Center

Treatments:

Olanzapine
Risperidone